SEARCH OUR PAGES

CoVepiT

CoVepiT

To conduct its COVID-19 prophylactic vaccine program, OSE Immunotherapeutics :

–  Leverages its expertise in the selection and optimization of peptides of interest and its Memopi® epitope (neo-epitopes) optimization technology, recently successfully
validated in the first step of a Phase 3 clinical testing for Tedopi® (a combination of antitumor neo-epitopes) to increase the memory immune response of T lymphocytes against specific antigens.

–  Uses artificial intelligence algorithms to accelerate optimization of these neo- epitopes and increase their immunogenicity capacity to induce robust T cell
memory immunity.

–  The first preclinical results are expected at the start of the second half of 2020 and, if possible, a clinical trial is considered before the end of 2020.

Using bioinformatics approaches and algorithms for predicting immunogenicity in the virus genome, OSE Immunotherapeutics’ R&D team has screened a large number of peptides derived from different proteins of SARS-CoV-2, SARS-CoV (virus responsible for SARS disease) and MERS-CoV (coronavirus of the Middle East respiratory syndrome) and selected the immuno-dominant epitopes from 4 major proteins of coronaviruses. OSE Immunotherapeutics is collaborating with deeptech company
MAbSilico to benefit from its know-how and versatile solutions in artificial intelligence algorithms to accelerate optimization of these neo-epitopes and increase their immunogenicity capacity to induce robust T cell memory immunity.

covid_19

To date, more than 20,000 SARS-CoV-2 neo-epitopes and as many peptide / HLA structural models
have been evaluated. OSE Immunotherapeutics has selected the most specific epitopes with high
potential for immunogenicity to move into preclinical testing and validate efficacy of the vaccine.
The Company expects the first preclinical results at the start of the second half of 2020 and, if
possible, to launch a clinical trial before the end of 2020.